Introduction
The ets oncogene (v-ets) was originally discovered as part of a fusion protein (gag-myb-ets) expressed by an avian transforming retrovirus, E-26, which transforms myeloblasts and erythroblasts in vitro and causes mixed erythroid-myeloid leukemia in vivo (Seth et al., 1992; Sharrocks et al., 1997; Watson et al., 1990) . V-ets contains an 85 amino acid sequence, the ets domain, which has been also identi®ed in various cellular proteins including Ets1, Ets2, Elk1, Fli1 and others (Seth et al., 1992; Sharrocks et al., 1997) . The ets family genes encode transcription factors, which regulate gene expression by interacting with speci®c purine-rich core sequences (C/AGGAA/T) that have been found in a large number of cellular and viral enhancers and promoters including proto-oncogenes and cytokines (Janknecht and Nordheim, 1993; Seth et al., 1992; Sharrocks et al., 1997; Wasylyk et al., 1993) . Ets genes have been shown to transform NIH3T3 cells and induce tumor formation in nude mice (Hart et al., 1995; Seth and Papas, 1990; Seth et al., 1989) .
Similar to the human ETS1 5'¯anking sequence, the mouse Ets1 gene promoter contains a GC-rich region upstream of multiple mRNA initiation sites and lacks both TATA sequences and a CAAT box (Jorcyk et al., 1991 (Jorcyk et al., , 1997 Majerus et al., 1992; Oka et al., 1991) . We have identi®ed consensus recognition sites for several transcription factors that may regulate the mouse Ets1 promoter, including AP1, RARs, Ets1 and NFkB (Jorcyk et al., 1997) . Several other agents that are known to upregulate Ets1 transcription, include RA, TNF-alpha, VEGF, and TPA Gilles et al., 1996; Wang et al., 1997) .
Ets1 gene can be activated by several mechanisms to become an ecient transforming gene. For example, in MuLV-induced rat T-cell lymphomas, Ets1 expression is upregulated due to the proviral insertion upstream of the ®rst exon of the gene (Bellacosa et al., 1994) . In contrast, the ectopic expression of the ETS1 gene in human colon cancer cell lines reduced the rate of the anchorage-independent growth in a dose dependent manner (Suzuki et al., 1995) . It has been shown that RA reduces the anchorage-independent growth of the human colon cancer cells (Hoosein et al., 1988; Niles et al., 1988) suggesting that RA may reduce the tumorigenicity of human colon cancer cells through upregulation of ETS1 expression.
Retinoic acid is a natural morphogen and plays a key role(s) in development and dierentiation of various cell types (Glass et al., 1990) . RA exerts its biological response through interaction with nuclear retinoic acid receptors, which belong to the steroid hormone receptor super family of transcription factors (Linney, 1992) . There are two families of RA receptors: the retinoid X receptors (RXR) and the retinoic acid receptors (RAR) (Lohnes et al., 1994) . Both RARs and RXRs consist of three receptor subtypes, alpha, beta and gamma, which are ligand-inducible transcription factors (Mangelsdorf et al., 1992) . Once activated, these receptors regulate transcription by interacting with RA response elements Pu-G-T/G-T-C-A, directly repeated 1 ± 5 bp apart in the promoter of target genes (Leid et al., 1992) .
Although the mechanism(s) by which RA is able to regulate the function of osteoblasts is not as yet fully ascertained, the RA mediated induction of at least one bone related gene product, parathyroid hormonerelated peptide, has been shown to involve interaction via a functional binding site, for the transcription factor Ets1 (Karperien et al., 1997) . Moreover, Ets1 is Oncogene (2000 Oncogene ( ) 19, 1969 Oncogene ( ± 1974 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: A Seth We dedicate this manuscript to the memory of Takis S Papas, a kind and generous colleague and friend, who was known for his pioneering work on the Ets family geneshighly expressed in bone during bone formation and remodeling and is associated with tissue remodeling and branching morphogenesis, processes that involve the degradation and remodeling of the extracellular matrix (Karperien et al., 1997; Kola et al., 1993; Maroulakou et al., 1994) .
Ets1 has been shown to interact with the`quintessential' osteoblast transcription factor CbfA1 (Ducy et al., 1997; Kim et al., 1999; Sun et al., 1995) . Thus the genetic programs regulated by Ets1 may signi®cantly aect the development and dierentiation of osteoblasts. We have shown that Ets1 is induced by the potent bone morphogen retinoic acid in dierentiating P19 embryonic carcinoma cells (Kola et al., 1993) . Elucidating regulatory mechanisms for direct interaction of RA with the Ets1 promoter would demonstrate that Ets1 can mediate retinoic acid eects.
To study the role of Ets1 in bone development, we have examined the mechanism of its activation by retinoic acid in the osteoblastic MC3T3-E1 cell line. Here, we demonstrate that all-trans-retinoic acid (atRA) induces the expression of Ets1 mRNA by 19-fold in 48 h in osteoblast-like cells and that the Ets1 promoter contains a functional RAR responsive element.
Results

Ets1 mRNA expression is induced by retinoic acid in MC3T3-E1 cells
In order to investigate the eects of retinoic acid on Ets1 expression in osteoblast like cells, MC3T3-E1 a b c Figure 1 Retinoic Acid induces Ets1 mRNA. MC3T3-E1 cells were treated with or without 1 mM all-trans-retinoic acid, and 10 mg of total RNA was examined at the indicated times. Expression of Ets1 mRNA was detected by Northern blot hybridization and quanti®ed relative to GAPDH expression (see Materials and methods). (a) Induction of Ets1 transcript by atRA for up to 48 h. The Northern blots used for 0.5 ± 4 h atRA treatment were exposed for 3 days. The Northern blots used for 24 ± 48 h treatment were exposed overnight to the X-ray ®lm. (b) Long term eects of atRA on Ets1 expression. Lanes 1 ± 6; untreated controls, lanes 7 ± 12; 1 mM all-trans-RA. The Northern blot was exposed overnight to the X-ray ®lm. (c) atRA is necessary for sustained induction of Ets1. MC3T3-E1 cells grown in medium with 1 mM atRA for 48 h and then in atRA free medium for another 24 or 48 h
Ets1 is upregulated by retinoic acid A Raouf et al cultures were treated with all-trans-retinoic acid (atRA) for 0.5 ± 48 h and the expression of Ets1 transcript was determined by Northern blot analysis ( Figure 1a ). Relative to GAPDH, we observed a 3.4-fold increase in the Ets1 mRNA levels after 4 h of treatment with atRA and 19-fold after 48 h. This induction of Ets1 mRNA can be maintained for at least 14 days ( Figure  1b ). In the absence of atRA at the level of Ets1 transcript was substantially reduced over 24 h and returned to basal levels after 48 h ( Figure 1c ) suggesting that atRA is required for the sustained induction of Ets1 mRNA levels. Interestingly, the mRNA expression of Ets2 (Figure 2 ), Fli1 and Elk1 (data not shown) transcription factors was not induced by atRA.
Actinomycin D inhibits atRA mediated induction of Ets1 mRNA expression
It has been shown that the retinoic acid regulation of gene expression occurs at both transcriptional and post-transcriptional levels (Inoue et al., 1996; LaRosa and Gudas, 1998; Mahadevan and Edwards, 1991) . In order to investigate the nature of induction of Ets1 mRNA levels by atRA, MC3T3-E1 cells were treated with a transcription initiation inhibitor, actinomycin D (Act D) and a protein synthesis inhibitor, cycloheximide (CHX) subsequent to a 24 h atRA administration. Treatment of cells with CHX for 4 h increased Ets1 mRNA levels. This superinduction is not unique to Ets1, as CHX treatment also induced the Ets2 gene ( Figure 2 ). Cycloheximide is known to increase the mRNA levels of other transcription factors such as cmyc, c-fos, and egr-1 by stabilizing their message (Greenberg et al., 1986; Suva et al., 1991) . In contrast, actinomycin D inhibited the induction of Ets1 mRNA by atRA yet had no eect on CHX stabilization of Ets1 mRNA for up to 4 h ( Figure 3 ).
RA receptor expression profile in the MC3T3-E1 cells
To determine the expression status of the RA receptors in the MC3T3-E1 cells, we treated the culture with atRA for various times and the expression of RARs and RXRs was examined by Northern blot analysis ( Figure 4 ). Our results indicate that RARb expression is induced by atRA and that RXRa and RXRb transcript levels are not signi®cantly altered following atRA treatment (Figure 4a,b) . However, we found that the expression of RARg is moderately enhanced in the presence of atRA, whereas RXRg is undetectable (Figure 4b ).
The Ets1 promoter has a functional RA responsive element
Our results showed that RA regulates Ets1 gene expression at the level of transcription. Therefore, we analysed 2.1 kb 5'¯anking region of the mouse Ets1 gene promoter for consensus retinoic acid responseelements. Interestingly, we found four half-sites located at 794 (RARE I), 7152 (RARE II), 71765 (RARE III), and 72252 (RARE IV) base pairs up stream of the translation start (Figure 5a ). Other regulatory elements that we identi®ed within the Ets1 promoter include the consensus binding sites for AP1, AP2, SP1 and an EBS. The proximal RARE I site is conserved between human, rat and mouse Ets1 promoters, suggesting that this site may be important for RAmediated regulation of this gene.
To determine whether retinoic acid receptors directly bind Ets1 RARE sites, electrophoretic mobility shift assays (EMSA) were performed with in vitro expressed RARb protein and 32 P-labeled oligonucleotide contain- Figure 3 Transcriptional activation of Ets1 by atRA. MC3T3-E1 cells were treated with either 1 mM all-trans-retinoic acid for 24 h or with CHX (1 mg/ml) for 4 h prior to treatment with Act D (2 mg/ml). Total RNA was extracted on the indicated times after actinomycin D treatment, Northern blotted and hybridized with a probe for Ets1, stripped, and reprobed for GAPDH expression Figure 2 Cycloheximide (CHX) superinduces Ets1 and Ets2 mRNA. MC3T3-E1 cells were pretreated with 1 mM all-transretinoic acid for 24 h and then treated with 1 mg/ml CHX in the presence of atRA as indicated above lanes. Ten mg of total RNA was analysed at indicated times and the same blot was hybridized serially with probes for Ets1, Ets2, and GAPDH. Lanes 1, no treatment; 2, 24 h atRA treatment; 3, 25 h treatment with atRA; 4, 1 h treatment with CHX in presence of atRA; 5, 28 h treatment with atRA; 6, 4 h treatment with CHX in presence of atRA; 7, 48 h treatment with atRA; 8, 24 h treatment with CHX in presence of atRA Figure 5b show that RARb form a complex with RARE I and excess unlabeled RARE I oligonucleotide completely abolishes the protein : DNA complex formation, demonstrating the speci®city of this interaction. In contrast, neither a mutant oligonucleotide, nor any of the other RARE sites (RARE II, III or IV) were able to signi®cantly compete with this binding site, suggesting that RARb binds speci®cally to the RARE I site in the Ets1 promoter (Figure 5b ). DNA binding with 32 Plabeled oligonucleotides corresponding to other RARE sites (II, III and IV) was also tested. However, no protein : DNA complexes were detected with RARb, RARg, or RXRa (data not shown) which further indicates that only the RARE I binds to the retinoic acid receptor proteins.
To demonstrate the functionality of RARE I site we constructed three Ets1-Luciferase promoter constructs, pLucE1P2.1, and pLucE1P0.7 and pLucE1P1.5 ( Figure  6 ). pLucE1P2.1 contains all four consensus RARE sites and pLucE1P0.7 contains the two proximal RAREs (RARE I and RARE II). pLucE1P1.5 lacks the proximal RAREs but does contain the distal RAREs (RARE III and RARE IV). Retinoic acid treatment of transfected MC3T3-E1 cells increased the transcriptional activity of pLucE1P2.1 and pLucE1P0.7 by 2-and 2.3-fold respectively and did not aect the activity of pLucE1P1.5 ( Figure 6 ). atRA treatment of cells transfected with the control vector lacking Ets1 promoter sequences did not alter the expression of the reporter gene. Ets1 is upregulated by retinoic acid A Raouf et al Discussion RA is a natural morphogen, which can function as a dierentiating agent in many cell types. For example, ETS1 mRNA expression is upregulated during RA induced dierentiation of both the human neuroblastoma cell line, LA-N-5 and the embryonic carcinoma cell line P19 (Kola et al., 1993; Thiele et al., 1988) . In this study we demonstrated that atRA increases the expression of Ets1 mRNA by 19-fold in 48 h in the MC3T3-E1 cells. The inhibition of this induction with actinomycin D suggests that RA regulation of Ets1 expression occurs at the transcriptional level. The transcriptional regulation of Ets1 by RA is further demonstrated through EMSA and transient transfection assays. Through gel retardation assays we have identi®ed a RA-responsive element (RARE I) which is located 94 bp upstream of the translational start site, which forms protein : DNA complexes with RARb, RARg, and RXRa. However, RARE II, III, and IV failed to form protein : DNA complexes. Similar to our ®ndings with Ets1 promoter, Suva et al. (1991 Suva et al. ( , 1994 have shown that induction of egr1 promoter by RA requires only a single half-site, and that this half site is recognized by all three RARs.
Transient transfection of MC3T3-E1 cells revealed that RA induces the transcriptional activity of pGL3E1P0.7 plasmid containing *700 bp of the identi®ed Ets1 regulatory region placed in front of the luciferase gene. Our transient transfection and EMSA results demonstrate that RARE I is a functional RA-responsive element, mediating the regulatory eect of RA on the Ets1 gene expression. The RA activation of the Ets1 promoter shown through our transient transfection assays is signi®-cantly less than the mRNA induction of the endogenous Ets1 gene detected by Northern blots. This dierence could be due to the presence of additional RA-responsive motifs present outside of the 2.1 kb promoter region analysed here. Previous studies have demonstrated that the ®rst intron of Ets1 contains elements necessary for tissue speci®c expression (Jorcyk et al., 1997) . However, our data suggests that induction of Ets1 gene transcription by RA is mediated in part through direct interaction between RARs with RARE I in the Ets1 promoter. Induction of Ets1 mRNA by atRA is maximal after 48 h suggesting that de novo protein synthesis may be required for initiation of transcription. In addition, cycloheximide treatment resulted in superinduction of Ets1 mRNA, as similarly shown for transcription factors, egr1 and c-myc (Davido and Mendelow, 1994; Lau and Nathans, 1987; Suva et al., 1991) . Previously it was reported that the Ets2 mRNA and not the Ets1 mRNA was superinduced in presence of CHX in regenerating liver (Bhat et al., 1987) . Here we show that both Ets1 and Ets2 mRNAs are superinduced by CHX, which may simply be due to cellspeci®c dierences similar to those previously demonstrated for c-myc (Greenberg et al., 1986) . In mouse ®broblastic cell line BALB/c-3T3, c-myc mRNA is superinduced by CHX whereas in the rat pheochromocytoma cell line PC12, CHX has no eect on the cmyc mRNA expression (Greenberg et al., 1986) . Superinduction of Ets1 mRNA by CHX is likely due to the enhanced mRNA stability, brought about by loss of transcriptional repressors and/or mRNA degrading enzymes.
The multiple eects of RA on cell function suggests the existence of regulatory interactions with other factors, such as Ets proteins, which may be key mediators of its outcomes.
For example, the RA induction of PTHrP, a bone related gene, which lacks RAREs, has been shown to be mediated by a functional Ets1 binding site in its promoter (Karperien et al., 1997) . Thus the mechanisms by which RA regulates gene expression may include the activation of Ets1 and its target genes.
Materials and methods
Cell culture
MC3T3-E1 cells were maintained in alpha modi®ed minimal essential medium supplemented with 10% fetal calf serum (FCS, Gibco ± BRL) and 10% antibiotic mix. Cultures were maintained at 378C in fully humidi®ed atmosphere of 5% CO 2 and 95% oxygen. For the purpose of this study, cells were plated at a density of 2.5610 4 cell/cm 2 . Once 80% con¯uent, cells were treated with 2 or 10% FCS and either 1 mM all-trans-retinoic acid (atRA, Sigma) or 2 mg of Actinomycin D (dactinomycin, Sigma) per ml or 1 mg of cycloheximide (Sigma) per ml or DMSO (Sigma). To study the eects of Act D and CHX on the Ets1 expression regulation by atRA, MC3T3-E1 cells were treated with alltrans-RA for 24 h prior to addition of CHX or Act D to the culture media.
RNA isolation, Northern blot analysis and quantification
Total cellular RNA was isolated by guanidinium isothiocyanate and phenol extraction as described (Chomczynski and Sacchi, 1987) . Total RNA (7 ± 15 mg) was size fractionated using a 1.2% agarose gel containing 2% formaldehyde and transferred to a nylon membrane using capillary transfer method. Northern blot analysis was carried out using probes speci®c to Ets1, Ets2, Elk1, Fli1. Probes (2610 6 c.p.m./ml) were made using random priming kit (Amersham-Pharmacia Biotech) and hybridization was carried out at 428C over night. The blots were washed at 658C for total of 1 h and exposed to Kodak X-ray ®lm.
The autoradiographs were scanned on a HP Scan Jet 5200C and bands were quantitated by the IP Lab Gel Scienti®c Image Processing program (Signal Analytics). Ets1 bands were normalized to their respective GAPDH bands.
Electrophoretic mobility shift assay
RA receptor proteins were made using an in vitro transcription and translation kit, according to the manufacturer's protocol (TNT kit, Promega). Retinoic acid receptor expression vectors were generous donations of Dr TM Underhill (University of Western Ontario, Canada). To analyse protein : DNA interactions, synthetic oligonucleotides corresponding to RARE I were annealed and labeled with a 32 P-dCTP and gel puri®ed (Mandel). Oligonucleotides corresponding to other Ets1 RARE half-sites located at 794, 7152, 71765 and 72252 were used as competitors. 5 ml of freshly in vitro synthesized protein was allowed to bind to oligonucleotide probes in the presence or absence of competitors for 20 min on ice (106binding buer: 200 mM Tris-HCl pH 7.5, 500 mM NaCl, 10 mM MgCl 2 2 mM EDTA and 5 mM DTT). Subsequently protein : DNA complexes were analysed through a non-denaturing 4% polyacrylamide gel containing 0.46TBE. The polyacrylamide gel was ®xed with 10% acetic acid, 20% methanol, 5% glycerol and 65% water, dried and exposed to Kodak X-ray ®lm.
Plasmid construction and transfections
To study the eects of RA on the Ets1 transactivation, three Ets1 promoter constructs were made. pLucE1P2.1 construct was generated by inserting a Fok1-Fok1 (2.1 kb) fragment of the Ets1 promoter isolated from Lambda DBA1 (Jorcyk et al., 1997) at the BglII site of the promoterless luciferase reporter gene in the plasmid pGL3-basic (Promega). pLucE1P0.7 construct was made by HindIII digestion of the pLucE1P2.1 and inserting the 692 bp fragment at the HindIII site of the pGL3-basic vector. PGL-3 plasmid contains no minimal promoter. pLucE1P1.5 containing RAREs III and IV was constructed by inserting the 1.5 kb HindIII digested Ets1 promoter fragment into a pGL3 derivative that contains a minimal promoter. MC3T3-E1 cells were transfected with 2 mg of pLucE1P2.1, pLucE1P0.7, pLucE1P1.5 or the empty pGL3 vector using 5 ml lipofectamine agent according to the manufacturer's protocol (Gibco ± BRL). Cells were incubated in media containing DNA-lipofectamine complexes for 5 h and immediately after transfection, cells were treated with either control medium or medium supplemented with 1 mM all-trans-RA and 2% or 10% FCS for 48 h. Cell extracts were prepared using luciferase detection kit according to the manufacturer's protocol (Promega). Luciferase activity was determined with a luminometer and normalized relative to total protein content as measured by Bradford assay (BioRad). The transfection experiments were repeated three times.
